Vascular Endothelial Growth Factor Expression in Correlation with Stage Juvenile Nasopharyngeal Angiofibroma

Ifiq Budiyan Nazar, Yussy Afriani Dewi, Agung Dinasti Permana


Background: Juvenile Nasopharyngeal Angiofibroma (JNA) is a benign tumor of mesenchymal tissue, originating from the stromal and blood vessels with dense collagen. However, JNA has a malignant tumor-like property because it can cause erosion of surrounding bone. Vascular Endothelial Growth Factor (VEGF) plays a role in the angiogenesis process. The expression of VEGF is the best marker to determine the occurrence of angiogenesis in JNA. This study aimed to determine the correlation between VEGF expression and JNA clinical stage.

Methods: This was a cross-sectional correlational analytic observational study on medical records and paraffin blocks of all patients with JNA at Dr. Hasan Sadikin General Hospital Bandung during the period of 2016 to 2019. Immunohistochemistry examination of VEGF expressions was performed and VEGF expression was rated based on staining intensity, percentage distribution, and histoscore. Data were then analyzed using the Spearman correlation test.

Results: Of 24 patients, 23 males and 1 female, 58% demonstrated a strong intensity of staining. The positivity of VEGF cell percentage was identified as 26–50% (n=6 patients), 51–75% (n=11), and >75% (n=7). The median VEGF histoscores were 2.5, 6.5, and 12 in JNA stage I, stage II, and stage 3, respectively, with the greater VEGF histoscore had a higher clinical stage with a correlation coefficient of (rs) 0.723 (p=0.002).

Conclusions: There is a strong correlation between increased VEGF expression and JNA clinical stage. VEGF expression can be used as a prognostic factor of JNA.


Angiogenesis, juvenile nasopharyngeal angiofibroma, staging, vascular endothelial growth factor

Full Text:



Shancez-Romero C, Carlos R, Molina JPD, Thompson LDR, de Almeida OP, Pina AR. Nasopharyngeal angiofibroma: a clinical, histopathological and immunohistochemical study of 42 cases with emphasis on stromal features. Head Neck Pathol. 2018;12(1):52–61

Anggreani L, Adham M, Musa Z, Lisnawati, Bardosono S. Gambaran ekspresi reseptor estrogen β pada angiofibroma nasofaring belia dengan menggunakan pemeriksaan imunohistokimia. ORLI. 2011;41(1):8–16

Sun X, Guo L, Wang H, Yu H, Wang J, Meng X, et al. The presence of tumor-infiltrating IL-17 producing cells in juvenile nasopharyngeal angiofibroma tumor microenvironment is a poor prognostic factor. Am J Otolaryngol. 2014;35(5):582–8

Nicolai P, Schreiber A, Villaret AB. Juvenile angiofibroma: evolution of management. Int J Pediatr. 2012: 412545

Garcea MF, Yuca SA, Yuca K. Juvenile Nasopharyngeal Angiofibroma. Eur J Gen Med. 2010;7(4):419–25

Persky M., Manolidis. S. Vascular tumors of the head and neck. In; Johnson JT, Rosen CA. Editors. Bailey’s head and neck surgery-otolaryngology 5th (ed). Baltimore: Lippincott Williams & Wilkins: 2014.p.1999–2031

Adham M, Zahara NP, Suroyo I, Lisnawati, Bardosono S. Relationship of radiological and surgical variables and vascular endothelial growth factor expression with recurrence in juvenile nasopharyngeal angiofibroma. Journal of Physic: Conference Series. 2018;1073(4):042038

Dewi YA, Nazar IB. Management of juvenile nasopharyngeal angiofibroma in a refferal hospital in West Java, Indonesia. Althea Medical Journal. 2020;7(1):45–50.

Li W, Ni Y, Lu H, Hu L, Wang D. Current perspectives on the origin theory of juvenile nasopharyngeal angiofibroma. Discov Med. 2019;27(150): 245–54

Liu Z, Wang J, Wang H, Wang D, Hu L, Liu Q, et al. Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis. Acta Otolaryngol. 2015; 135(1): 51–7

Zhang M, Sun X, Yu H, Hu L, Wang D. Biological distinctions between juvenile naopharyngeal angiofibroma and vascular malformation: immunohistochemical study. Acta Histochem. 2011;113(6):626–30

Melincovici CS, Boşca AB, Şuşman S, Márginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67

Le T, New J, Jones JW, Usman S, Yalamanchali S, Tawfik O, et al. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma. Int Forum Allergy Rhinol. 2017;7(10):973–79

Saylam G, Yücel OT, Sungur A, Onerci M. Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol. 2006;70(2):227–34

Schuon R, Brieger J, Heinrich YR, Szyfter W, Mann WJ. Immunohistochemical analysis of growth mechanisms in juvenile nasopharyngeal angiofibroma. Eur Arch Otorhinolaryngol. 2007;264(4):389–94

Hota A, Sarkar C, Gupta SD, Kumar R, Bhalla AS, Thakar A. Expression of vascular endothelial growth factor in juvenile angiofibroma. Int J Pediatr Otorhinolaryngol. 2015;79(6):900–2

Saniasiaya J, Abdullah B, Ramli RR. Surgical management and outcome of juvenile nasopharyngeal angiofibroma in a single centre: a fifteen year experience. Egypt J Ear Nose Throat Allied Sci. 2016:18(1): 39–41

Ralli M, Fusconi M, Visconti IC, Martelucci S, de Vincentis M, Greco A. Nasopharyngeal angiofibroma in an elderly female patient: a rare case report.. Mol Clin Oncol. 2018; 9(6):702–4

Pandey P, Mishra A, Tripathi AM, Verma V, Trivedi R, Singh HP, et al. Current molecular profile of juvenile nasopharyngeal angiofibroma: first comprehensive study from India. Laryngoscope. 2016;127(3): E100–106.

Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med. 2016;48(7):e242.


 This Journal indexed by


Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats